Weight loss · Mississippi
Weight loss and obesity studies in Mississippi
11 studies have at least one recruiting site in Mississippi. Weight-management research includes trials of new medicines, devices, diets and lifestyle programs for people with overweight or obesity, and studies of weight-related conditions such as fatty liver disease.
11 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Gulfport, MS + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Ridgeland, MS + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Fayette, MS + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Gulfport, MS + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche
- Location
- Olive Branch, MS + 44 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Ridgeland, MS + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Jackson, MS + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Eli Lilly and Company
- Location
- Olive Branch, MS + 28 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- Fayette, MS + 69 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Corxel Pharmaceuticals
- Location
- Ridgeland, MS + 32 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteers
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
University of Mississippi Medical Center
- Location
- Jackson, MS
- Eligibility basics
- Ages 18–75
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Can I join a weight loss study if I already take a GLP-1 medicine?
It depends on the study. Many exclude people currently or recently on weight-loss medicines; others are designed specifically for them. The listing’s eligibility criteria and the study team are the only reliable answer.